Health Condition 1: C419- Malignant neoplasm of bone and articular cartilage, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
TATA MEMORIAL HOSPITAL
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with histologically proven Ewingâ??s sarcoma of the dura, and vertebral/paravertebral/Chest wall/calvarial/skull base with intradural extension 2.Treated with radical intent at TMH/ACTREC from January 2013 to December 2030 (Partly treated in TMH/ACTREC or treatment advised from here) 3.Any age 4.With at least 6 months of follow-up
Exclusion criteria
Exclusion criteria: 1.Patients treated with palliative intent 2.Less than 6 months of follow-up 3.Referred outside or defaulted for treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess patterns of failure in patients with meningeal Ewingâ??s sarcoma either and patients with ewings sarcoma secondarily involvings the meninges.Timepoint: after completion of treatment during follow-up every 3 months for first 2 to3 years, every 6 months for next 2 years, and annually thereafter up to 5 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess outcomes [Local control (LC), Local Relapse Free Survival (LRFS), Disease Free Survival (DFS), Overall Survival (OS) in patients with meningeal sarcoma 2.To assess the relevance of systemic staging using FDG PET CECT 3.To assess prognostic factors for relapse 4.To compare LC, LRFS, DFS, OS & patterns of failure with vertebral/paravertebral/chestwall/calvarial/skull baseEwingâ??s sarcoma with intradural extension (secondary involvement) Timepoint: At baseline,after completion of treatment; during follow-up every 3 months for first 2to3 years, every 6 months for next 2 years & annually thereafter up to 5 years. | — |
Countries
India
Contacts
Public ContactDr Jifmi Jose Manjali
Tata Memorial Hospital
Outcome results
None listed